Cellular Biomedicine Group, Inc., a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, entered into a lease agreement to build an approximately 22,000 square foot facility in Rockville, Maryland.

The Rockville campus will augment its global research and development capabilities and to support clinical trials in the United States centering around both its liquid tumor and solid tumor candidates.

According to company officials, the Rockville facility is strategically located in the heart of Maryland's life sciences center, on Medical Center Drive, an area commonly referred to as "DNA Alley."

The facility, when completed, will allow the development of new technology and preparation for clinical trials according to U.S. Food and Drug Administration (FDA) guidelines. The company intends for the facility to have a capacity to accommodate early phases of CBMG's clinical trials for its liquid and solid tumor candidates.

"This new site is poised to foster strategic partnership, new innovations, and support the continued development of CBMG's cell therapy based immune-oncology assets in the US that have showed promise in early proof-of-concept trials," said Tony (Bizuo) Liu, CEO for the Company.

Cellular Biomedicine Group, Inc. conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.